Individuals with comorbidities such as hypertension and respiratory system and cardiovascular diseases may have a greater susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a study suggests.
Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) show superiority over other blood pressure (BP)-lowering medications in terms of reducing high-sensitivity C-reactive protein (hs-CRP) and procalcitonin levels in COVID-19 patients with pre-existing hypertension, as shown in a recent study.
The use of Janus kinase (JAK) inhibitors for the treatment of inflammatory bowel diseases (IBDs) and other immune-mediated diseases may increase the risk of herpes zoster infection, reports a recent meta-analysis.
An end-of-treatment (EOT) HBsAg level 40 IU/mL appears to be a useful cutoff value for predicting hepatitis B virus (HBV) infection relapse following cessation of either entecavir or tenofovir disoproxil fumarate (TDF) treatment, as shown in a study. Specifically, low levels of EOT HBsAg and baseline HBV DNA or HBcrAg translate to reduced odds of having relapse.
Upper respiratory (UR) and atypical symptoms are more likely to occur in children with symptomatic pharyngitis and group A Streptococcus (GAS) on throat culture identified as carrier than those who are acutely infected, according to a study.
There appears to be no evidence of the SARS-CoV-2 virus in the semen of patients recovering from COVID-19 a month after diagnosis, according to a study, suggesting that the virus is unlikely to gain entry into testicular cells through an ACE2/TMPRSS2-mediated mechanism.
In the fight against the coronavirus disease 2019 (COVID-19) pandemic, healthcare workers experience a range of physical symptoms, which are strongly related to psychological distress, according to a study, suggesting a bidirectional relationship between physical symptoms and psychological outcomes.